COMMUNIQUÉS West-GlobeNewswire

Garaherb Claims Evaluated: Complete Scientific Investigation of Ingredients' Effectiveness
20/03/2026
An informational report compiling GaraHerb's publicly available product materials, ingredient-level research references, formulation transparency considerations, and consumer details for 2026 Aurora, CO, March 20, 2026 [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
20/03/2026
SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Publication relative à des notifications de transparence
20/03/2026
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 20 mars 2026 , 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Publication relating to transparency notifications
20/03/2026
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
20/03/2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc [...]
SafeSpace Global Corporation Reports Q2 Fiscal 2026 Financial Results; Company Transitions from Pre-Revenue to Revenue-Generating Stage, Expands Footprint with Nashville Office, and Initiates Steps Toward National Exchange Uplisting
20/03/2026
KNOXVILLE, TN., March 20, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions company dedicated to [...]
Disclosure of a transparency notification from Aberdeen Group plc
20/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the [...]
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
20/03/2026
EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live [...]
Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors
20/03/2026
--Veteran global investment leader joins neurotechnology company advancing AI-enabled brain health platforms-- BALTIMORE, March 20, 2026 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions , a neurotechnology company [...]
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
20/03/2026
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
GUERBET : Mise à disposition du Document d’enregistrement universel 2025
20/03/2026
Mise à disposition du Document d’enregistrement universel 2025 Villepinte, le 20 mars 2026, Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, a déposé son [...]
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
20/03/2026
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 March 2026 at 15.40 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Scientist Challenges CERN and Industry to Public ‘Known Dataset Test’ to Prove 3D-Flow Can Save Billions and Millions of Lives
20/03/2026
Crosetto Foundation calls for transparency at the 2026 Total Body PET Conference to evaluate technology capable of detecting early-stage cancer currently missed by existing systems DALLAS, March 20, 2026 (GLOBE NEWSWIRE [...]
CapsoVision Announces $14 Million Private Placement Financing
20/03/2026
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the “Company”) (NASDAQ: CV), a commercial-stage medical [...]
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
20/03/2026
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on [...]
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
20/03/2026
Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 (GLOBE NEWSWIRE) -- REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD Biopharma executive with more than 35 years of leadership across C-suite and [...]
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
20/03/2026
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world [...]
WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial
20/03/2026
IRVINE, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox today announced the successful treatment of the first U.S. patient in the p 48 and p64 MW HPC i n An eurysm O cclusion (PIANO) IDE trial, evaluating the [...]

Pages